within Pharmacolibrary.Drugs.ATC.H;

model H01AC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Mecasermin rinfabate is a combination of recombinant human insulin-like growth factor 1 (rhIGF-1, mecasermin) and recombinant human insulin-like growth factor binding protein 3 (rhIGFBP-3). It was developed for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. The drug is not currently approved and is not on the market.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data specific for mecasermin rinfabate in humans is available. Estimates below are generic or based on related IGF-1 compounds. Parameters left blank where no direct data is available.</p><h4>References</h4><ol><li><p>Kemp, SF (2007). Mecasermin rinfabate. <i>Drugs of today (Barcelona, Spain : 1998)</i> 43(3) 149–155. DOI:<a href=&quot;https://doi.org/10.1358/dot.2007.43.3.1079876&quot;>10.1358/dot.2007.43.3.1079876</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17380212/&quot;>https://pubmed.ncbi.nlm.nih.gov/17380212</a></p></li><li><p>Williams, RM, et al., &amp; Dunger, DB (2008). Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. <i>Expert opinion on drug metabolism &amp; toxicology</i> 4(3) 311–324. DOI:<a href=&quot;https://doi.org/10.1517/17425255.4.3.311&quot;>10.1517/17425255.4.3.311</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18363546/&quot;>https://pubmed.ncbi.nlm.nih.gov/18363546</a></p></li><li><p> (2005). Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. <i>Drugs in R&amp;D</i> 6(2) 120–127. DOI:<a href=&quot;https://doi.org/10.2165/00126839-200506020-00008&quot;>10.2165/00126839-200506020-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15777106/&quot;>https://pubmed.ncbi.nlm.nih.gov/15777106</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01AC05;
